Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference
25 mai 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results
11 mai 2021 06h30 HE
|
Beam Therapeutics
Data from Beam’s Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52% Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 ...
Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting
27 avr. 2021 16h41 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Publishes Data Highlighting Ability to Rationally Design Base Editors for Precise Editing
20 avr. 2021 10h12 HE
|
Beam Therapeutics
Data Published in The CRISPR Journal Describe Inlaid Base Editors (IBEs) that Enhance Editing Efficiency and Capability, an Advancement of the Company’s Pioneering Work in Developing Base Editors ...
Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
15 mars 2021 06h30 HE
|
Beam Therapeutics
Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing Team...
Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer
15 mars 2021 06h15 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference
04 mars 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Acquisition of Guide Therapeutics
23 févr. 2021 08h34 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it has...
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors
19 janv. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today...
Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors
11 janv. 2021 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...